Yunnan Baiyao Group Raises RMB 1.394 Billion To Expand Production Capacity
This article was originally published in PharmAsia News
To quickly grow its production capacity, Yunnan Baiyao Group will issue 50 million private shares at RMB 27.87 per share to raise RMB 1.394 billion. The new fund will be used to invest in the company's overall relocation project, expand production of self-developed products, as well as provide capital to the company's subsidiary, Yunnan Pharmaceutical. After completion of the issuance, output of the firm's self-developed products will be boosted; this is expected to raise the revenue ratio contributed by products with high profit margins. (Click here for more - Chinese Language)
You may also be interested in...
From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.